HMA updates guide on renewal of drug authorisations in light of EU pharmacovigilance law
This article was originally published in SRA
Executive Summary
The Heads of Medicines Agencies in the EU has significantly updated its guideline on how applicants and member states should handle renewals of drug marketing authorisations under the mutual recognition and decentralised procedures1. The update pertains to the new requirements introduced by the EU pharmacovigilance legislation (Directive 2010/84/EU)2.
You may also be interested in...
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.